SSelectStock
Sign in

PANACEABIOPanacea Biotec Limited

Pharma · Biotechnology · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

548.85
0.00%
53Average

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)3,361.70
P/E
P/B4.27
PEG
ROE %-0.60
ROCE %-4.40
Debt / Equity0.03
EPS-0.86
Revenue Growth %1.00
Profit Growth %-12.20
Dividend Yield %0.00
Promoter Holding %72.65
FII Holding %0.13
DII Holding %
Beta0.14

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG80%548.85521.90615.852.49
HOLDConviction 55%

The picture

  • Debt/Equity: 0.03
  • Promoter holding: 72.7%
  • RSI: 55
  • Price vs EMA21: above
  • Price vs SMA50: above
  • 3-month return: +50.9%
  • Pullback to 21-EMA signal (setup quality 80%)

Bull case

  • Debt/Equity: 0.03
  • Promoter holding: 72.7%
  • RSI: 55
  • Price vs EMA21: above

Bear case

  • Revenue growth: 1.0% YoY
  • Profit growth: -12.2% YoY
  • MACD: bearish
  • Volume: 0.3x 20-day average

Key risks

  • Elevated volatility / drawdown profile — size positions accordingly
  • Weak fundamentals — technical strength may not sustain
  • Revenue growth: 1.0% YoY
  • Profit growth: -12.2% YoY

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹548.85
Stop Loss
₹515.05
risk 6.2%
Target 1 (1.5R)
₹599.55
+9.2%
Target 2 (3R)
₹650.26
+18.5%
Support (20d)
₹520.25
Resistance (52w)
₹647.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹33.80/share
ATR (volatility)
₹26.95
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹26.95). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
27
Technical
66
Momentum
74
Risk (safety)
40

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.45%
82
HESTERBIO 3.09%
81
LUPIN 1.44%
80
SUNPHARMA 1.23%
80
CORONA 0.78%
79

About

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.